Health and Healthcare
Amgen, Finally Some Good News (AMGN, MRK)
Published:
Last Updated:
Shares of Amgen Inc. (NASDAQ: AMGN) are seeing a small gain in after-hours trading.
The troubled biotech giant announced that findings from its head-to-head, double-blind trial comparing the effects of denosumab in post-menopausal women with low bone mass transitioned from weekly alendronate (FOSAMAX(R)) versus continued alendronate therapy on bone mineral density (BMD). This study was a one-year non-pivotal Phase III study and it demonstrated superior results for the primary and all secondary endpoints.
The primary endpoint was in the total hip and it was listed as 80% greater in the group. This was a twice-yearly subcutaneous injection in a double-blind group of 504 women who suffered from low BMD.
FOSAMAX is an osteoporosis drug from Merck & Co. (NYSE: MRK).
Jon C. Ogg
May 19, 2008
Jon Ogg produces and edits the "10 Stocks Under $10" newsletter and he does not own securities in the companies he covers.
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.